Evonik Industries Ag · XETR:EVK
Evonik Industries — Q2 2026 Earnings Presentation
39 slides from Evonik Industries's earnings presentation, August 2026
Slide 1: Evonik Company Presentation Q2 2026
Evonik Company Presentation Q2 2026 1 August-September 2026 | Evonik 2026 Company Presentation
Slide 2: Agenda
Agenda 1 Evonik at a glance 1 Evonik at a glance 2 Strategy and capital allocation 2 Strategy and capital allocation 3 Q2 2026 results 3 Q2 2026 results 2 August-September 2026 | Evonik 2026 Company Presentation
Slide 3: Evonik at a glance
Evonik at a glance €14.1 bn Custom Solutions Sales Innovation-driven businesses with €1.9 bn (13.3%) tailored and Adj. EBITDA (margin) science-based LEADING solutions €695 m (37%) BEYOND Free Cash Flow (conversion) CHEMISTRY Advanced Technologies 6.1% Efficiency-driven businesses with a high ROCE le
Slide 4: We deliver products and solutions that improve life, every day
We deliver products and solutions that improve life, every day Nutrition Electronics Pharma & Health Care Every second Every second, Every third Consumer microchip over 1000 chicken in the US is acid-reflux patients is fed with produced using feel better thanks methionine hydrogen to Evonik tablet f
Slide 5: Our product portfolio: End market split and product examples
Our product portfolio: End market split and product examples 0-4% 5-10% 10-15% 15-20% Other Industries Automotive, Transportation & Machinery ▪ Gas-separation Membranes ▪ Coating additives for topcoats / under body coating ▪ Silanes and high-purity H2O2 for electronics industry / ▪ Silica / Silanes
Slide 6: Why invest in Evonik?
Why invest in Evonik? EVONIK IS INDUSTRY’S SUPERFORCE Tailored solutions and industrial excellence Leading Portfolio Sustainable Innovation Regional Balance Team Excellence Shareholder Return We are best positioned We are banking on We are striving for a We are engaged as a = We are committed to for
Slide 7: Agenda
Agenda 1 Evonik at a glance 1 Evonik at a glance 2 Strategy and capital allocation 2 Strategy and capital allocation 3 Q2 2026 results 3 Q2 2026 results 7 August-September 2026 | Evonik 2026 Company Presentation
Slide 8: Leading Portfolio: New segment structure with tangible benefits
Leading Portfolio: New segment structure with tangible benefits Advantages Custom Employee Advanced Differentiated Leaner commitment Solutions steering organisation for specific Technologies role Custom Solutions Advanced Technologies Tailored solutions for our customers Technology & cost leadership
Slide 9: Custom Solutions and Advanced Technologies – Overview and KPIs
Leading Portfolio: Custom Solutions and Advanced Technologies – Overview and KPI’s Custom Solutions Advanced Technologies Sales EBITDA Sales EBITDA Financials €5.5 bn €909 m €6.0 bn €944 m 2025 ROCE EBITDA margin ROCE EBITDA margin 10% 17% 7% 16% Role Stronger role as growth driver with superior EBI
Slide 10: Sustainable Innovation: Main growth driver for the long-run
Sustainable Innovation: Main growth driver for the long-run Product innovation Process innovation €1.5 bn additional sales Drive cost leadership and by 2032 at >20% margin reduce GHG2 emissions Next Generation Solutions1 with Next Generation Technology superior sustainability profile projects with a
Slide 11: Sustainable Innovation: NGS with a superior sustainability profile
Sustainable Innovation: NGS with a superior sustainability profile and above-average growth Sales growth 2024-2030E (in %) NGS sales share in 2025 (in %) ▪ Deliver superior sustainability 48% benefits to our customers ▪ Adress increasing customer demand for sustainable solutions +3pp ▪ Substitute le
Slide 12: Regional Balance: Aiming for 1/3 of sales in each region
Regional Balance: Aiming for 1/3 of sales in each region to be close to our customers Target Americas EMEA Asia-Pacific sales share 1/3 1/3 1/3 20251 ~32% ~44% ~24% Capital allocation over proportionally With local-for-local production geared towards Asia in coming years Shift of management position
Slide 13: We are “Team Excellence”
We are “Team Excellence”: Derived from our core values – deeply rooted within Evonik ▪ We strive for excellence in everything we do – across businesses and functions ▪ We set ourselves ambitious targets Excellence ▪ We hold ourselves accountable to reach these targets (e.g. in compensation) ▪ We val
Slide 14: We continue to execute on our strategy
We continue to execute on our strategy Today In the coming years Weak demand and structural headwinds At least some demand improvement We control our own destiny – We have more potential acting from a position of for improvement strength with our strategy execution ROCE ~11% as soon as possible → Co
Slide 15: Growth aspirations in existing products complemented with long-term opportunities
Growth aspirations in existing products to be complemented with more long-term oriented opportunities NEW! Specific contributions … long-term growth As in the next years … presented opportunities at 2025 CMD Existing products in new markets Growth PA12 | Germany Silica | United States with strong gr
Slide 16: Efficiency program Evonik Tailor Made extended until 2029
Efficiency program Evonik Tailor Made extended until 2029: Additional 3,200 FTEs to be reduced 2023-2026 2027-2029 NEW! 2023-2026 Reorganization …2027-2029 Business Procurement “Evonik Tailor “Evonik Tailor Made” extended and expanded optimization optimization Made” + All cost savings and optimizati
Slide 17: Capital allocation priorities remain unchanged – new dividend policy
Capital allocation priorities remain unchanged – new dividend policy based on payout ratio Use of cash … unchanged 1 priorities … 2 and disciplined 3 INVESTMENTS INTO ATTRACTIVE ADDITIONAL ORGANIC GROWTH DIVIDEND VALUE CREATION Unchanged Unchanged NEW! Until 2027: ~50% ~50% New dividend policy De-le
Slide 18: New dividend policy: attractive dividend with increased financial flexibility
New dividend policy: Combining an attractive dividend with increased financial flexibility New dividend policy to be established in two steps 1 Dividend ▪ Rigid dividend of €1.17 not adequate in this tough market environment proposal for FY 2025 €1 and for a company in transformation ▪ Transition ye
Slide 19: Agenda
Agenda 1 Evonik at a glance 1 Evonik at a glance 2 Strategy and capital allocation 2 Strategy and capital allocation 3 Q2 2026 results 3 Q2 2026 results 19 August-September 2026 | Evonik 2026 Company Presentation
Slide 20: Second quarter ahead of plan – FY guidance raised
Second quarter ahead of plan – FY guidance raised Q2 adj. EBITDA of €630 m (+24% yoy) ahead of expectations mainly due to strong Advanced Technologies Strong Q2 FCF of €49 m (prior year: -€211 m) thanks to better earnings and less bonus payout Efficiency program Evonik Tailor Made extended until 202
Slide 21: Q2 adj. EBITDA of €630 m ahead of expectations
Q2 adj. EBITDA of €630 m ahead of expectations mainly due to strong Advanced Technologies Adj. EBITDA (in € m) / Margin (in %) Drivers of Q2 performance ▪ Solid performance in Custom Solutions (+7% yoy) +24% ▪ Strong Advanced Technologies (+25% yoy) 630 − High volumes in Organics (esp. Crosslin
Slide 22: Strong Q2 FCF of €49 m thanks to better earnings and less bonus payout
Strong Q2 FCF of €49 m thanks to better earnings and less bonus payout Free Cash Flow (in € m) Drivers of H1 performance Q2 H1 ▪ Free cash flow significantly up in H1 (yoy) 232 despite rather stable adj. EBITDA (+3% in H1) 49 − Lower NWC outflow due to strict -211 NWC management − Lower bonu
Slide 23: FY 2026 outlook raised considerably
FY 2026 outlook raised considerably: Adj. EBITDA between €2.0 and 2.2 bn expected Adj. EBITDA (in € bn) Outlook by segment “€2.0 - 2.2 bn” Stable on Custom prior-year level “€1.7 - 2.0 bn” Solutions 1.9 (2025: €909 m) Considerably above Advanced prior-year level Technologies (2025: €944 m) Signif
Slide 24: Free Cash Flow outlook confirmed: Targeting ~40% conversion
Free Cash Flow outlook confirmed: Targeting ~40% conversion Free Cash Flow (in € m) / Conversion rate1 (in %) Building blocks for FCF development CCR1 37% ~40% Better operating result 695 Disciplined capex Lower bonus payments (for 2025) NWC with certain headwind from inflation 2025 2026E 1
Slide 25: Q2 2026 results overview
Q2 2026 results overview Sales (in € m) Sales (yoy) Adj. EBITDA (in € m) Volume Price +7% +7% 3,893 FX Other 630 (Q2 2025: 3,499) (Q2 2025: 509) -2% -1% Capex1 (in € m) Free Cash Flow (in € m) Adj. EPS (in €) 180 49 0.65 (Q2 2025: 176) (Q2 2025: -211) (Q2 2025: 0.34) 1. Cash outflows for investments
Slide 26: Custom Solutions
Custom Solutions Q2 26 vs. Q2 25 Volume Price FX Other ▪ Good volume and price development; FX headwind +4% +3% -1% -2% subsiding Sales ▪ Sales and order intake on elevated levels esp. in Additives, (in € m) however normalisation towards quarter-end +4% Additives 1,367 1,422 1,334 --- Add
Slide 27: Advanced Technologies
Advanced Technologies Q2 26 vs. Q2 25 Volume Price FX Other Sales Inorganics (adj. EBITDA slightly down yoy) +7% +5% -1% -2% (in € m) ▪ Silica benefits from network optimization Inorganics +9% ▪ Hydrogen Peroxide lower due to license income in previous --- 1,647 year, good volume growth for sem
Slide 28: Infrastructure / Other
Infrastructure / Other Adj. EBITDA (in € m) Thereof: Infrastructure +163% ▪ Oxeno (C4): benefiting from higher margins due to war in the Middle East 100 ▪ Infrastructure: as usual high level of 47 stability 38 26 Q2 2025 Q1 2026 Q2 2026 7 Thereof: Other -11 -49 -40 -74
Slide 29: Additional indications for FY 2026
Additional indications for FY 2026 Sales Around €15 bn (previously: between €13.5 and 14.5 bn; 2025: €14.1 bn) ROCE Slightly above prior-year level (previously: on prior-year level; 2025: 6.1%) Capex1 ~€750 m (2025: €748 m) EUR/USD sensitivity2 +/-1 USD cent = -/+ ~€5 m adj. EBITDA (FY basis) Adj. D
Slide 30: Adjusted income statement Q2 2026
Adjusted income statement Q2 2026 in € m Q2 2025 Q2 2026 ∆ Sales 3,499 3,893 11% Adj. EBITDA 509 630 24% Adj. tax rate (18%) Depreciation & amortization -259 -260 ▪ Adj. tax rate lower than long-term average Adj. EBIT 250 370 48% (~30%) due to higher earnings share in countries with lower tax rates
Slide 31: Cash flow statement Q2 2026
Cash flow statement Q2 2026 in € m Q2 2025 Q2 2026 CF from operating activities Income before financial result and income taxes (EBIT) 236 163 ▪ Lower (reported) EBIT as starting point Depreciation and amortization 260 376 ▪ Higher impairments, mainly C4 ∆ Net working capital -237 -180 Change in pro
Slide 32: Net financial debt development H1 2026
Net financial debt development H1 2026 3,620 3,311 45 64 34 466 636 404 Dec 31, 2025 F from C ash outflows Dividend payout C Net interest ddition / A Other June 30, 2026 Net financial operating for investments payments reduction in Net financial debt activi
Slide 33: Development of debt and leverage over time
Development of debt and leverage over time Total 3.0x 2.3x 2.4x 2.6x Leverage1 Net financial debt (€3,620 m) 3,310 3,253 3,311 3,620 ▪ Net financial debt up mainly due to Net financial dividend payment debt ▪ Net financial debt leverage stable at (in € m) 1.8x2 Pension provisions (€1,538
Slide 34: Segment overview by quarter
Segment overview by quarter Sales (in € m) Q1/25 Q2/25 Q3/25 Q4/25 FY 2025 Q1/26 Q2/26 Custom Solutions 1,427 1,367 1,340 1,359 5,492 1,334 1,422 Advanced Technologies 1,601 1,511 1,445 1,415 5,973 1,450 1,647 Infrastructure / Other1 749 621 606 629 2,604 643 824 Evonik Group 3,777 3,499 3,391 3,403
Slide 35: Update on business optimization programs
Update on business optimization programs Secure competitive position and deliver savings High Performance Coating & Crosslinkers Amino Acids Silica/Silanes Health Care Polymers Adhesive Resins (i-Chain) Start date Q2 2023 Q1 2024 Q4 2023 Q1 2024 Q1 2024 Q1 2024 Full potential End of 2026 End of 2027
Slide 36: Upcoming IR events
Upcoming IR events Conferences & roadshows Upcoming reporting dates & events August 5, 2026 Roadshow Frankfurt (Oddo) November 3, 2026 Q3 2026 Reporting September 2, 2026 Roadshow London (Citi) March 4, 2027 Q4/FY 2026 Reporting September 2, 2026 Roadshow Amsterdam May 4, 2027 Q1 2027 Reporting Sept
Slide 37: Evonik Investor Relations Team
Evonik Investor Relations Team Christoph Finke Cédric Schupp Senior Vice President Investor Relations Director Investor Relations & ESG +49 174 9931647 +49 173 2552453 christoph.finke@evonik.com cedric.schupp@evonik.com Katharina Gayk Johanna Göbel Specialist Investor Relations Senior Manager Invest
Slide 38: Disclaimer
Disclaimer In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the oper
Slide 39: © evonik
© evonik